MedTrace Logo

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

NCT06220123 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2025-07-22

No results posted yet for this study

Summary

This study is designed to evaluate the efficacy and safety of SHR-2004 injection in preventing postoperative venous thromboembolism in patients undergoing ovarian cancer surgery.

Conditions

  • Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Interventions

DRUG

SHR-2004

Investigational product arm: SHR-2004

DRUG

Enoxaparin Sodium Injection; Rivaroxaban Tablets

Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets

Sponsors & Collaborators

  • Beijing Suncadia Pharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-16
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06220123 on ClinicalTrials.gov